癌症创新药支付管理政策建议——以英国癌症药物基金(CDF)改革历程为鉴  

Policy Suggestions on Payment Management of Cancer Innovative Drugs--Taking the Reform Process of CDF in UK as a Reference

作　　者：刘跃华 郭武栋 赵琨 刘昭 Liu Yuehua;Guo Wudong;Zhao Kun;Liu Zhao(National Health Development Research Center/National Center for Drug and Technology Assessment,Beijing,100191)

机构地区：[1]国家卫生健康委卫生发展研究中心/国家药物和卫生技术综合评估中心,北京100191

出　　处：《中国医疗保险》2020年第5期76-80,共5页China Health Insurance

基　　金：2020年国家医疗保障局医疗保障事业管理中心委托项目:中国卫生技术评估机制建设研究。

摘　　要：英国癌症药物基金(CDF)成立后面临预算超支、基金管理效率低下等多项问题,针对运行中出现的问题,通过历次改革持续完善管理办法,在药品准入和退出机制、审批流程规范化、预算管理风险分摊协议等方面做出优化调整。以上经验教训值得我国在制定创新药准入及管理政策方面参考,不断探索未来创新药支付政策突破点。建议成立多元化筹资的癌症创新药物基金,建立标准的目录准入及退出机制,关注真实世界数据在支付决策中的作用,探索合理超支分担科学管理的预算协议等。After the establishment of the Cancer Drugs Fund(CDF) in the UK, it came up with a number of problems such as budget overruns and inefficient fund management. In response to these problems, it continuously optimized management methods through several reforms, such as defining drug entry and exit mechanisms, optimizing standardization of processes and signing risk management agreements. The above lessons are worthy of reference for China in formulating policies for management of innovative drugs. The establishment of a multi-funded cancer innovative drug fund, the fomulation of a standard entry and exit mechanism, a focus on the role of real-world data in payment decisions, and the exploration of a reasonable and over-expenditure scientific management budget agreement will be breakthroughs in future innovation drug payment policy reforms.

关 键 词：英国癌症药物基金 癌症创新药 支付政策 预算协议管理 

分 类 号：F840.684[经济管理—保险] C913.7[社会学]